17(ss)-hydroxysteroid dehydrogenase type 1 is a predictive factor in premenopausal hormone receptor positive breast cancer treated with tamoxifen

被引：0
|
作者：
Kallstrom, A-C
Salme, R.
Ryden, L.
Gunnarsson, C.
Nordenskjold, B.
Stal, O.
机构：
[1] Helsingborg Hosp, Helsingborg, Sweden
[2] Univ Hosp, Linkoping, Sweden
[3] Univ Lund Hosp, S-22185 Lund, Sweden
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S84 / S85
页数：2
相关论文
共 50 条
  • [41] OPTIMAL SYSTEMIC THERAPY FOR PREMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE BREAST CANCER
    Davidson, N.
    BREAST, 2013, 22 : S18 - S18
  • [42] LHRH agonists: treatment for hormone-receptor-positive breast cancer in premenopausal women
    Nature Clinical Practice Oncology, 2007, 4 (9): : 500 - 501
  • [43] Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer
    Jankowitz, Rachel C.
    McGuire, Kandace P.
    Davidson, Nancy E.
    BREAST, 2013, 22 : S165 - S170
  • [44] Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer
    O'Regan, Ruth M.
    Zhang, Yi
    Fleming, Gini F.
    Francis, Prudence A.
    Kammler, Roswitha
    Viale, Giuseppe
    Dell'Orto, Patrizia
    Lang, Istvan
    Bellet, Meritxell
    Bonnefoi, Herve R.
    Tondini, Carlo
    Villa, Federica
    Bernardo, Antonio
    Ciruelos, Eva M.
    Neven, Patrick
    Karlsson, Per
    Mueller, Bettina
    Jochum, Wolfram
    Zaman, Khalil
    Martino, Silvana
    Geyer, Charles E.
    Jerzak, Katarzyna J.
    Davidson, Nancy E.
    Coleman, Robert E.
    Ingle, James N.
    van Mackelenbergh, Marion T.
    Loi, Sherene
    Colleoni, Marco
    Schnabel, Catherine A.
    Treuner, Kai
    Regan, Meredith M.
    JAMA ONCOLOGY, 2024, 10 (10) : 1379 - 1389
  • [45] Overexpression of 17β-Hydroxysteroid Dehydrogenase Type 1 Increases the Exposure of Endometrial Cancer to 17β-Estradiol
    Cornel, Karlijn M. C.
    Kruitwagen, Roy F. P. M.
    Delvoux, Bert
    Visconti, Laura
    Van de Vijver, Koen K.
    Day, Joanna M.
    Van Gorp, Toon
    Hermans, Rob J. J.
    Dunselman, Gerard A.
    Romano, Andrea
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (04): : E591 - E601
  • [46] Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients
    Hosny, Marwa M.
    Sabek, Nagwan A.
    El-Abaseri, Taghrid B.
    Hassan, Fathalla M.
    Farrag, Sherif H.
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2016, 2016
  • [47] p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients
    Stendahl, Maria
    Nilsson, Sofie
    Wigerup, Caroline
    Jirstrom, Karin
    Jonsson, Per Ebbe
    Stal, Olle
    Landberg, Goran
    INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) : 2851 - 2858
  • [48] The Cost-Effectiveness of Adjuvant Tamoxifen Treatment of Hormone Receptor-Positive Early Breast Cancer Among Premenopausal and Perimenopausal Ghanaian Women
    Addo, Rebecca
    Haas, Marion
    Goodall, Stephen
    VALUE IN HEALTH REGIONAL ISSUES, 2021, 25 : 196 - 205
  • [49] 17β hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma:: a correlation to clinicopathological parameters
    Suzuki, T
    Moriya, T
    Ariga, N
    Kaneko, C
    Kanazawa, M
    Sasano, H
    BRITISH JOURNAL OF CANCER, 2000, 82 (03) : 518 - 523
  • [50] Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer
    Maselli, Angela
    Parlato, Stefania
    Puglisi, Rossella
    Raggi, Carla
    Spada, Massimo
    Macchia, Daniele
    Pontecorvi, Giada
    Iessi, Elisabetta
    Pagano, Maria Teresa
    Cirulli, Francesca
    Gabriele, Lucia
    Care, Alessandra
    Vici, Patrizia
    Pizzuti, Laura
    Barba, Maddalena
    Matarrese, Paola
    Pierdominici, Marina
    Ortona, Elena
    CELLS, 2019, 8 (07)
12345